Studying the onset of action of somituximab (Mirvetuximab)

Remission of symptoms or tumor response (such as tumor shrinkage) occurs within 4 to 6 weeks after treatment with somituximab (Mirvetuximab), and significant therapeutic effects in more ovarian cancer patients usually appear within 2 to 3 months after treatment.

Specifically, somituximab can selectively act on tumor cells and reduce damage to healthy cells by targeting the mechanism of FRα. This precise treatment method allows patients to obtain results in a shorter period of time, but the onset time of the drug is still affected by many factors, including the patient's physical condition, the severity of the disease, and drug tolerance.

In clinical studies, the efficacy of somituximab is usually evaluated based on patients' progression-free survival (PFS) and overall survival (OS). Preliminary research data shows that somituximab can effectively prolong the survival and improve the quality of life of patients with advanced ovarian cancer. Most patients show some tumor shrinkage or symptom relief within the first few months of treatment, especially those who are FRα-positive.

However, it’s important to note that not all patients will see significant results within the same amount of time. For some patients, tumors may respond more slowly to treatment and may take longer to show significant effects. Therefore, although the onset of action of somituximab is typically four to six weeks, some patients may require a longer treatment period to see more significant effects.

In general, somituximab has a relatively quick onset of action, and some patients may begin to feel the effects 4 to 6 weeks after treatment. However, the final treatment effect and onset of action are still affected by many factors, and patients should work closely with their doctor to adjust their treatment plan based on their individual treatment response.

Reference materials:https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761310s000lbl.pdf